Quarterly Result13 Nov 2025, 07:52 pm
Marksans Pharma Reports Record Q2 FY26 Performance with Highest-Ever Quarterly Revenue of X720 Cr and 44% QoQ Growth in EBITDA
AI Summary
Marksans Pharma Ltd. has reported the financial results for the quarter and half-year ended on September 30, 2025. The company has recorded the highest-ever quarterly revenue of X720 Cr, a 16% sequential growth. The EBITDA and PAT grew 44% and 70% quarter-on-quarter, reflecting the benefits of operating leverage. The US region recorded solid growth, demonstrating resilience amid macro challenges, supported by stabilizing tariff conditions, timely order book execution, and meaningful traction from new product launches. The UK market also witnessed improved demand despite continued pricing pressures. The company remains optimistic about sustaining this momentum into the second half of the year.
Key Highlights
- Q2 operating revenue stood at Rs. 720.4 cr., up by 12.2% YoY
- Gross profit stood at Rs. 411.8 cr., up by 7.4% YoY
- EBITDA stood at Rs. 144.5 cr., with a margin of 20.1%
- US market recorded revenues of Rs. 387.3 cr. in Q2FY26
- Cash generated from operations at X 75.2 cr during H1FY26